Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Rabab El EitAbdul Rahman ItaniFarah NassarNagham RasbiehMark JabbourAhmad SantinaGhazi ZaatariFrançois-Xavier MahonAli BazarbachiRihab R NasrPublished in: Cancer (2019)
Collectively, the ATO/IFN strategy has been demonstrated to have the potential to lead to durable remissions in TKI-resistant CML preclinical models and to overcome various TKI-specific mechanisms of resistance.